The DOI matches its Crossref record.
Covid-19: South Africa pauses use of Oxford vaccine after study casts doubt on efficacy against variant
Abstract
Covid-19: South Africa pauses use of Oxford vaccine after study casts doubt on efficacy against variant Elisabeth MahaseRollout of the Oxford-AstraZeneca covid-19 vaccine in South Africa has been paused after a study in 2000 healthy and young volunteers reported that it did not protect against mild and moderate disease caused by the new variant (501Y.V2) that emerged there.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
As new variants of the virus regularly emerge, coronavirus is here to stay, and further lockdown/restrictions are likely despite the roll out of the vaccination programme.
“As new variants of the virus regularly emerge (e.g. Delta, Omicron), the expectation is that coronavirus is here to stay (Mahase, 2021), and further lockdown/restrictions are likely despite the roll out of the vaccination programme.”
From Living through lockdown: A qualitative exploration of individuals' experiences in the UK. (2022) · cites this paper as Mahase, 2021
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 2
- 10.1136/bmj.n296 · DOI · Paper page
- 10.1136/bmj.n86 · DOI
Cited by
Sorted by citations
Mbunge, E., Batani, J., Gaobotse, G., & Muchemwa, B. (2022) · Global Health Journal · doi:10.1016/j.glohj.2022.03.001 · Cited by 219
Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters
Abdelnabi, R., Boudewijns, R., Foo, C. S.-Y., Seldeslachts, L., Sánchez-Felipe, L., Zhang, X., Delang, L., Maes, P., Kaptein, S. J. F., Weynand, B., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103403 · Cited by 103
“Notably, mutations found in the SARS-CoV-2 spike protein that may be associated with (i) more efficient human-to-human transmission, (ii) increased virulence, [7] and/or (iii) escape from naturally acquired [6] or vaccine-induced [8,9] immunity raise concerns.”
Tanzania's position on the COVID-19 pandemic
Mfinanga, S., Mnyambwa, N., Minja, D. T. R., Ntinginya, N., Ngadaya, E., Makani, J., & Makubi, A. N. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00678-4 · Cited by 54
Perception of COVID-19 Vaccination Amongst Physicians in Colombia
Alvarado-Socarras, J., Vesga-Varela, A. L., Quintero-Lesmes, D., Fama-Pereira, M. M., Serrano-Díaz, N., Vasco, M., Carballo-Zárate, V., Zambrano, L., Paniz-Mondolfi, A., & Rodríguez-Morales, A. (2021) · Vaccines · doi:10.3390/vaccines9030287 · Cited by 38
Perchetti, G. A., Zhu, H., Mills, M. G., Shrestha, L., Wagner, C., Bakhash, S. M., Lin, M. J., Xie, H. J., Huang, M.-L. W., Mathias, P. C., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27155 · Cited by 32
COVID-19 vaccine strategies for Aotearoa New Zealand: a mathematical modelling study
Nguyen, T., Adnan, M., Nguyen, B. P., de Ligt, J., Geoghegan, J. L., Dean, R. A., Jefferies, S., Baker, M. G., Seah, W. K. G., Sporle, A. A., et al. (2021) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2021.100256 · Cited by 24
“30 Although the range of estimated VE used in this study are plausible, in particular for the mRNA vaccines licensed in NZ, 11 the lower bounds of VE may need to be extended in the presence of variants of concern.”
Mehmood, A., Khan, S., Khan, S., Ahmed, S., Ali, A., Xue, M., ali, L., Hamza, M., Munir, A., Rehman, S. U., et al. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.02.058 · Cited by 30
“WHO is partnering with stakeholders around the world to help plan crucial measures in this process, and to promote equal access to secure and reliable COVID-19 vaccines for the billions of people who will need them (Mahase, 2021) Human beings have been using medicinal plants since ancient times.”
Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges
Kandimalla, R. J. L., Chakraborty, P., Vallamkondu, J., Chaudhary, A., Samanta, S., Reddy, P. H., Feo, V. D., & Dewanjee, S. (2021) · Biomedicines · doi:10.3390/biomedicines9111740 · Cited by 25
Comparative infectivity and pathogenesis of emerging SARS-CoV-2 variants in Syrian hamsters
Abdelnabi, R., Boudewijns, R., Foo, C., Seldeslachts, L., Sanchez-Felipe, L., Zhang, X., Delang, L., Maes, P., Kaptein, S., Weynand, B., et al. (2021) · bioRxiv · doi:10.1101/2021.02.26.433062 · Cited by 22
Disparities in global COVID-19 vaccination rates & allocation of resources to countries in need
Sen-Crowe, B., Mckenney, M., & Elkbuli, A. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2021.102620 · Cited by 21
“4 South Africa in February 2021 may also play a role in the low vaccination rates [13].”
InfluentialLiving through lockdown: A qualitative exploration of individuals' experiences in the UK.
Taylor, C., Lafarge, C., Cahill, S., Milani, R., & Görzig, A. (2022) · Health & Social Care in the Community · doi:10.1111/hsc.13772 · Cited by 19
“As new variants of the virus regularly emerge (e.g. Delta, Omicron), the expectation is that coronavirus is here to stay (Mahase, 2021), and further lockdown/restrictions are likely despite the roll out of the vaccination programme.”
Rabiu, M., & Iyaniwura, S. A. (2022) · Nonlinear Dynamics · doi:10.1007/s11071-022-07225-9 · Cited by 20
“351 variant of SARS-CoV2, which was the dominant strain of the virus in the country [33,34].”
BackgroundShukla, P., Pandey, P., Prasad, B., Robinson, T., Purohit, R., D'Cruz, L. G., Tambuwala, M. M., Mutreja, A., Harkin, J., Singh, T., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab496 · Cited by 16
“Furthermore, SARS-CoV-2 vaccines from Moderna, Pfizer-BioNTech, Novavax and Oxford-AstraZeneca have also been found to be less efficacious against South African population [21–24].”
InfluentialSARS-CoV-2: Vaccinology and Emerging therapeutics; Challenges and Future Developments
Adesokan, A. M., Obeid, M. A., & Lawal, A. F. (2022) · Therapeutic Delivery · doi:10.4155/tde-2021-0075 · Cited by 12
Mohammed, A. H., Hassan, B. A. R., Wayyes, A. M., Farhan, S., Al-ani, O., Blebil, A., Dujaili, J., & Othman, G. (2022) · Psychology Research and Behavior Management · doi:10.2147/prbm.s352811 · Cited by 9
Proactive debriefing to promote wellbeing in intensive care nurses: A protocol
Levido, A., Keogh, S. J., Jarrett, P., Crowe, L., & Coyer, F. M. (2024) · Australian Critical Care · doi:10.1016/j.aucc.2024.01.004 · Cited by 9
The Role of Symptom Clusters in Triage of COVID-19 Patients
Wojtusiak, J., Bagais, W. H., Vang, J., Guralnik, E., Roess, A., & Alemi, F. (2022) · Quality Management in Health Care · doi:10.1097/qmh.0000000000000399 · Cited by 10
“New variants of SARS-CoV-2 may manifest different symptoms.(3) Patient age groups have been shown to present with different COVID-19 symptoms.”
BackgroundPost-COVID-19 vaccination occurrence of splenic infarction due to arterial thrombosis
Anderson, A., Seddon, M., Shahzad, K., & Lunevicius, R. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-243846 · Cited by 6
Deb, P., Molla, M. M. A., Saif‐Ur‐Rahman, K., Das, M. C., & Das, D. (2021) · Egyptian Journal of Bronchology · doi:10.1186/s43168-021-00090-x · Cited by 7
The Trade-off Between Prioritization and Vaccination Speed Depends on Mitigation MeasuresPreprint
Agarwal, N., Komo, A., Patel, C., Pathak, P., & Unver, U. (2021) · medRxiv · doi:10.1101/2021.02.24.21252352 · Cited by 5
“There are also new strains of SARS-Cov-2, with differing levels of transmissibility and virulence [33, 34], and vaccine efficacy [35, 36, 37, 38].”
BackgroundHow South Africa is dragging its vaccine rollout back from the brink
Wadvalla, B.-A. (2021) · British medical journal · doi:10.1136/bmj.n1949 · Cited by 4
SARS-CoV-2 vaccines elicit differential Fc effector functions
Manamela, N. P., Motsoeneng, B. M., Spencer, H., Hermanus, T., Mzindle, N. B., Ayres, F., Makhado, Z., Serage, R., Gray, G., Bekker, L., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113084 · Cited by 3
Agwa, S. H. A., Elghazaly, H. A., El‐Meteini, M., Yahia, Y. A., Khaled, R., Elsamee, A. M. A., Darwish, R. M., M.Elsayed, S., Hafez, H., Mahmoud, B. S. F., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.817735 · Cited by 3
“…SARSCoV-2 genome, different genetic clades appeared in Hong Kong in the first 2 months after the identification of SARS-CoV-2 including the V, S, and L clades (To et al., 2021), these variants were thought to worsen vaccine potency (Mahase, 2021) and also cause reinfections (Zucman et al., 2021).”
BackgroundMusa, M., & Iyaniwura, S. (2021) · medRxiv · doi:10.1101/2021.10.23.21265421 · Cited by 2
“351 variant of SARS-CoV-2, which was the dominant strain of the virus in the country [40, 42].”
BackgroundKnowledge, attitudes and perceptions of a patient population on the COVID-19 vaccine rollout
Purasram, M., Bangalee, V., Oosthuizen, F., & Moodley, R. (2022) · Health SA = SA Gesondheid · doi:10.4102/hsag.v27i0.1845 · Cited by 1
“V2 variant, and so the rollout was halted (Mahase 2021).”
BackgroundRana, E. A., Dutta, P., Islam, M. S., Nizami, T. A., Das, T., Chowdhury, S., & Das, G. B. (2021) · medRxiv · doi:10.1101/2021.05.10.21256529 · Cited by 1
Zheng, S.-J. (2023) · The Scholarship Without Borders Journal · doi:10.57229/2834-2267.1017
“which resulted in a pause in South Africa (Mahase, 2021b).”
BackgroundInfluentialLiterature analysis of the efficacy of COVID-19 vaccinationsPreprint
Hulsen, T. (2022) · medRxiv · doi:10.1101/2022.12.24.22283835
“Mahase [24] published results from a Pfizer press release reporting that as shown 100% efficacy against SARS-CoV-2 in 12 to 15 year olds in the preliminary results of a phase III trial.”
BackgroundInfluentialOwolabi, A. T., Ayinde, K., Adejumo, T. J., Kasali, W. A., & Adewuyi, E. T. (2022) · Journal of the Nigerian Society of Physical Sciences · doi:10.46481/jnsps.2022.702 · Cited by 1
“V2 variant, which accounts for around 90% of cases in South Africa [39, 40].”
BackgroundThe effect of RNA and non-RNA vaccines in variants of Covid-19: A narrative review
Rahmannia, M., Abadi, S. R. F., Hasani, A. H. S., Khanali, F., Vosoughian, F., Mirzaei, R., & Esmaeili, H. (2021) · Pakistan Journal of Medical & Health Sciences · doi:10.53350/pjmhs211572112
Synopsis on COVID19 Vaccine Development
Watt, B. (2021) · Caribbean Medical Journal · doi:10.48107/cmj.2021.03.008
Haire, B. G. (2021) · Indian Journal of Medical Ethics · doi:10.20529/ijme.2021.020 · Cited by 1
“These include the issue of whether some vaccines are effective against emergent variants, (the AstraZeneca efficacy drops below 50% with some variants)(11) the problem of significantly reduced efficacy in people with HIV (Novavax efficacy dropped from 60% to 49% when HIV positive people were included in the analysis)(…”
Background
Metadata
- Authors
- Mahase, E.
- Affiliations
- BMJ Group (United Kingdom) (GB)
- Corresponding author
- Mahase, Elisabeth
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2021-02-08
- Volume
- 372
- Pages
- n372
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W3128959418
- Cited by
- 38
- References
- 0
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 1 · 2022: 13 · 2021: 20
- Type
- other
- Language
- en
- Open access
- closed
- Locations
- BMJ (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- COVID-19 pandemic, Oxford-AstraZeneca vaccine, vaccine efficacy, South Africa, young healthy volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
